PD-1 antibody and bevacizumab
Phase 2Monoclonal antibody
PD-1 antibody and bevacizumab is one of 65 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
PD-1 antibody and bevacizumab
SShanghai Zhongshan Hospital
Phase 2
Vermox
WWim Janssens
Preclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Zhongshan Hospital